Koch W, Kastrati A, Mehilli J, Böttiger C, von Beckerath N, Schömig A
Deutsches Herzzentrum München and 1. Medizinische Klinik rechts der Isar, Technische Universität München, Munich, Germany.
Circulation. 2000 Jul 11;102(2):197-202. doi: 10.1161/01.cir.102.2.197.
The renin-angiotensin system is thought to play a role in coronary thrombosis and restenosis. Plasma angiotensin I-converting enzyme (ACE) activity is associated with an insertion/deletion polymorphism in the gene coding for ACE. The objective of this study was to test the hypothesis that the D allele of the ACE gene is associated with a higher risk for restenosis after coronary stent placement.
This prospective study included 1850 consecutive patients with coronary artery disease who underwent intracoronary stent implantation. The adverse clinical events recorded were death, myocardial infarction, and target vessel revascularization. The primary end point of the study was restenosis (>/=50% diameter stenosis at follow-up angiography performed in 84% of the patients). The secondary end point was clinical outcome 1 year after the procedure. The restenosis rate at the 6-month angiographic follow-up was 32.8% in patients with the II genotype, 34.0% for patients with the ID genotype, and 31.2% for patients with the DD genotype (P=0.62). One-year event-free survival was 77.7% in patients with genotype II, 75.2% in patients with genotype ID, and 75.5% in patients with genotype DD (P=0.54). The lack of association was also present in the subgroup of patients with a low risk for restenosis: the restenosis rate was 21.7% in II carriers, 23.4% in ID carriers, and 19.7% in DD carriers (P=0.83).
The ACE DD genotype or D allele does not influence the 1-year clinical and angiographic outcome of patients undergoing coronary stent placement. These data suggest that routine determination of the ACE genotype may not help identify patients who are at a higher risk of thrombotic and restenotic events after coronary stent placement.
肾素-血管紧张素系统被认为在冠状动脉血栓形成和再狭窄中起作用。血浆血管紧张素I转换酶(ACE)活性与ACE编码基因中的插入/缺失多态性相关。本研究的目的是检验以下假设:ACE基因的D等位基因与冠状动脉支架置入术后再狭窄风险较高相关。
这项前瞻性研究纳入了1850例连续接受冠状动脉疾病治疗并进行冠状动脉内支架植入的患者。记录的不良临床事件包括死亡、心肌梗死和靶血管血运重建。研究的主要终点是再狭窄(在84%的患者中进行的随访血管造影显示直径狭窄≥50%)。次要终点是术后1年的临床结局。在6个月血管造影随访时,II基因型患者的再狭窄率为32.8%,ID基因型患者为34.0%,DD基因型患者为31.2%(P = 0.62)。基因型II患者的1年无事件生存率为77.7%,基因型ID患者为75.2%,基因型DD患者为75.5%(P = 0.54)。在再狭窄低风险患者亚组中也缺乏相关性:II携带者的再狭窄率为21.7%,ID携带者为23.4%,DD携带者为19.7%(P = 0.83)。
ACE DD基因型或D等位基因不影响接受冠状动脉支架置入患者的1年临床和血管造影结局。这些数据表明,常规检测ACE基因型可能无助于识别冠状动脉支架置入术后血栓形成和再狭窄事件风险较高的患者。